Subsequently, a novel predictive model based on three genes (IL6, IL1A, and CSF3) was constructed in our clinical cohort, which was independent of the IPI, but could predict the overall survival of DLBCL patients. Here, CSF3 is linked to diffuse large B-cell lymphoma.